Article
Oncology
S. Mollnar, P. Pondorfer, A-K Kasparek, S. Reinisch, F. Moik, M. Stotz, M. Halm, J. Szkandera, A. Terbuch, F. Eisner, A. Gerger, K. S. Kapp, R. Partl, S. Vasicek, T. Weiland, M. Pichler, H. Stoeger, D. Thurnher, F. Posch
Summary: In locally advanced head and neck squamous cell carcinoma patients, radiochemotherapy often leads to toxicities requiring treatment modifications, which can impact outcomes. While chemotherapy modifications did not significantly impact treatment outcomes, reductions in radiotherapy dose were associated with impaired long-term results.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Review
Oncology
Daniel R. Dickstein, Eric J. Lehrer, Kristin Hsieh, Alexandra Hotca, Brianna M. Jones, Ann Powers, Sonam Sharma, Jerry Liu, Vishal Gupta, Loren Mell, Zain Husain, Diana Kirke, Krzysztof Misiukiewicz, Marshall Posner, Eric Genden, Richard L. Bakst
Summary: Approximately one third of head and neck cancer patients are older adults, but they are significantly underrepresented in clinical trials. There is no clear consensus on the optimal treatment for older adults with head and neck cancer due to variations in their functional and performance status, medical comorbidities, and medication management. Novel predictive scores are being developed and ongoing clinical trials are investigating less intensive treatments for this population.
Article
Oncology
Robert L. Ferris, Jessica Moskovitz, Sheryl Kunning, Ayana T. Ruffin, Carly Reeder, James Ohr, William E. Gooding, Seungwon Kim, Brian J. Karlovits, Dario A. A. Vignali, Umamaheswar Duvvuri, Jonas T. Johnson, Daniel Petro, Dwight E. Heron, David A. Clump, Tullia C. Bruno, Julie E. Bauman
Summary: This study investigated the addition of ipilimumab to standard cetuximab-radiotherapy for the treatment of HNSCC. The results showed that the regimen was tolerable and achieved acceptable survival rates. Additionally, high expression of coinhibitory receptors on baseline tumor-infiltrating lymphocytes was associated with poorer disease-free survival.
CLINICAL CANCER RESEARCH
(2022)
Article
Otorhinolaryngology
Wataru Okano, Ryuichi Hayashi, Kazuto Matsuura, Takeshi Shinozaki, Toshifumi Tomioka
Summary: The study indicates that targeted neck dissection (ND) after definitive chemoradiotherapy is an effective intervention for patients with cervical disease recurrence, showing promising survival rates and control rates.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Article
Oncology
Maureen Bernadach, Michel Lapeyre, Anne-Francoise Dillies, Jessica Miroir, Melanie Casile, Juliette Moreau, Ioana Molnar, Angeline Ginzac, Nathalie Pham-Dang, Nicolas Saroul, Xavier Durando, Julian Biau
Summary: The study investigated predictive factors of toxicity of induction chemotherapy with TPF in locally advanced head and neck cancers, finding that nutritional status and hepatic dysfunction are significant risk factors to consider in therapeutic decisions.
Article
Nutrition & Dietetics
Takae Tsujimoto, Masafumi Wasa, Hidenori Inohara, Toshinori Ito
Summary: L-glutamine does not influence the survival of patients with locally advanced head and neck cancer receiving chemoradiotherapy.
Article
Oncology
Susanne Wiegand, Gunnar Wichmann, Jeannette Vogt, Kathrin Vogel, Annegret Franke, Thomas Kuhnt, Florian Lordick, Anne-Marie Scheuble, Peter Hambsch, Peter Brossart, Franz Georg Bauernfeind, Holger Kaftan, Georg Maschmeyer, Matthias Paland, Marc Muenter, Victor Lewitzki, Nicole Rotter, Carmen Stromberger, Marcus Beck, Steffen Dommerich, Thomas Christoph Gauler, Gunnar Hapke, Orlando Guntinas-Lichius, Ursula Schroeder, Martin Goerner, Matthias G. Hautmann, Felix Steger, Balint Tamaskovics, Anett Schmiedeknecht, Andreas Dietz
Summary: Most patients with head and neck squamous cell carcinoma (HNSCC) are diagnosed with locally advanced disease and can be treated with surgery and adjuvant radio(chemo)therapy or definitive chemoradiation. However, recurrence is common, especially in high-risk cases. The ADRISK trial aims to investigate whether the addition of pembrolizumab to the standard treatment improves event-free survival in locally advanced HNSCC patients. This ongoing prospective, randomized controlled trial is recruiting patients since August 2018.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Claire Petit, Benjamin Lacas, Jean-Pierre Pignon, Quynh Thu Le, Vincent Gregoire, Cai Grau, Allan Hackshaw, Bjorn Zackrisson, Mahesh K. B. Parmar, Ju-Whei Lee, Maria Grazia Ghi, Giuseppe Sanguineti, Stephane Temam, Maurice Cheugoua-Zanetsie, Brian O'Sullivan, Marshall R. Posner, Everett E. Vokes, Juan J. Cruz Hernandez, Zbigniew Szutkowski, Eric Lartigau, Volker Budach, Rafal Suwinski, Michael Poulsen, Shaleen Kumar, Sarbani Ghosh Laskar, Jean-Jacques Mazeron, Branislav Jeremic, John Simes, Lai-Ping Zhong, Jens Overgaard, Catherine Fortpied, Pedro Torres-Saavedra, Jean Bourhis, Anne Auperin, Pierre Blanchard
Summary: The network meta-analysis suggests that intensifying chemoradiotherapy, using hyperfractionated radiotherapy with concomitant chemotherapy or induction chemotherapy followed by chemoradiotherapy, could improve outcomes for locally advanced head and neck cancer patients.
Article
Multidisciplinary Sciences
Ana Maria Castro Ferreira, Joo Mauricio Carrasco Altemani, Ligia Traldi Macedo, Gustavo Jacob Lourenco, Carmen Silvia Passos Lima
Summary: This study investigated the impact of SNVs in genes of metabolic pathways on the outcome of advanced head and neck squamous cell carcinoma patients treated with CDDP chemoradiation. The results suggest that combined SNVs of CDDP metabolism may serve as independent prognostic factors and aid in selecting appropriate treatments for patients.
SCIENTIFIC REPORTS
(2023)
Article
Otorhinolaryngology
James Han, Kaveh Zakeri, Gabriel Raab, Jennifer Hesse, Achraf Shamseddine, Linda Chen, Yao Yu, Jung Julie Kang, Sean M. M. McBride, Nadeem Riaz, C. Jillian Tsai, Daphna Gelblum, Eric J. J. Sherman, Richard J. J. Wong, Loren Michel, Nancy Y. Y. Lee
Summary: This study reports the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation using carboplatin and paclitaxel. The results show that chemoradiation with carboplatin and paclitaxel is an effective treatment option for controlling locoregional recurrences and distant metastases, and improving progression-free survival and overall survival in these patients.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2023)
Article
Oncology
L. Belgioia, C. Becherini, A. Bacigalupo, P. Bonomo
Summary: Immunotherapy plays a significant role in the treatment of head and neck squamous cell carcinoma, but its role in upfront management of locally advanced disease and its integration with standard of care remains unclear.
Article
Oncology
Isaku Okamoto, Takuro Okada, Kunihiko Tokashiki, Kiyoaki Tsukahara
Summary: This study assessed the impact of head and neck photoimmunotherapy on the quality of life of patients with unresectable head and neck carcinoma. The results showed that there were no significant changes in the quality of life assessment parameters after treatment with head and neck photoimmunotherapy. For patients with unresectable head and neck carcinoma, this treatment provided good local control without decreasing the quality of life.
Article
Medicine, General & Internal
Qiuji Wu, Juan Wang, Shaojie Li, Jia Liu, Yanshuang Cheng, Jieying Jin, Yahua Zhong
Summary: This study compared the prognosis of patients with head and neck soft-tissue sarcoma treated with radiotherapy-based treatment versus surgery-based treatment. The results showed no significant difference in overall survival, distant metastasis-free survival, loco-regional relapse-free survival, and progression-free survival between the two groups. Older age was associated with poorer distant metastasis-free survival. Chemoradiotherapy may be an alternative treatment option for patients who are ineligible for surgery, refuse surgery, or have failed surgery.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Szu-Han Hu, Ming-Yii Huang, Chung-Yu Chen, Hui-Min Hsieh
Summary: This study examines the treatment trends and survival effects of locally advanced head and neck cancer patients in Taiwan before and after the coverage of cetuximab by the National Health Insurance. The study found an increasing trend in the utilization of cetuximab among these patients, but overall usage rates were low. Additionally, patients receiving cetuximab with other treatments had higher mortality risk compared to those receiving cisplatin.
Review
Pharmacology & Pharmacy
Huanhuan Wang, Zhuangzhuang Zheng, Yangyu Zhang, Chenbin Bian, Jindian Bao, Ying Xin, Xin Jiang
Summary: In this study, we systematically evaluated the treatment effectiveness and safety of locally advanced head and neck squamous cell carcinoma (HNSCC). The results showed that concurrent treatment with nimotuzumab or conventional concurrent chemo-radiotherapy (CCRT) had significantly better efficacy and long-term survival without increasing adverse events (AEs) compared to radiotherapy alone. Accelerated fractionated radiotherapy (AFRT) showed better efficiency but had higher AEs. Concurrent cetuximab combined with radiotherapy did not show a significant advantage over radiotherapy alone.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Oncology
Zhen Wang, Mohammed Nabhan, Steven E. Schild, Scott L. Stafford, Ivy A. Petersen, Robert L. Foote, M. Hassan Murad
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2013)
Letter
Oncology
Steven E. Schild, Sameer R. Keole, Robert L. Foote
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2013)
Article
Oncology
Grace K. Dy, Sumithra J. Mandrekar, Garth D. Nelson, Jeffrey P. Meyers, Araba A. Adjei, Helen J. Ross, Rafat H. Ansari, Alan P. Lyss, Philip J. Stella, Steven E. Schild, Julian R. Molina, Alex A. Adjei
JOURNAL OF THORACIC ONCOLOGY
(2013)
Article
Oncology
D. Rades, L. Dziggel, B. Segedin, I. Oblak, V. Nagy, A. Marita, S. E. Schild, N. T. Trang, M. T. Khoa
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Article
Oncology
N. D. Seibold, S. E. Schild, M. P. Gebhard, F. Noack, D. Rades
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Article
Oncology
N. D. Seibold, S. E. Schild, M. P. Gebhard, F. Noack, D. Rades
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Article
Oncology
D. Rades, T. Veninga, A. Bajrovic, J. H. Karstens, S. E. Schild
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Article
Oncology
L. Dziggel, B. Segedin, N. H. Podvrsnik, I. Oblak, S. E. Schild, D. Rades
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Review
Oncology
Ronald Chow, Peter Hoskin, Steven E. Schild, Srinivas Raman, James Im, Daniel Zhang, Stephanie Chan, Nicholas Chiu, Leonard Chiu, Henry Lam, Edward Chow, Michael Lock
RADIOTHERAPY AND ONCOLOGY
(2019)
Article
Oncology
Daniel F. Craft, Jarrod Lentz, Mike Armstrong, Madeline Foster, Justin Gagneur, Daniel Harrington, Steven E. Schild, Mirek Fatyga
PRACTICAL RADIATION ONCOLOGY
(2020)
Correction
Oncology
Ronald Chow, Peter Hoskin, Steven E. Schild, Srinivas Raman, James Im, Daniel Zhang, Stephanie Chan, Nicholas Chiu, Leonard Chiu, Henry Lam, Edward Chow, Michael Lock
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Oncology
Steven E. Schild, Xiaofei Wang, Christine M. Bestvina, Terence Williams, Greg Masters, Anurag K. Singh, Thomas E. Stinchcombe, Joseph K. Salama, Steven Wolf, Tyler Zemla, Narjust Duma, Stephen G. Chun, Arya Amini, David Kozono, Colleen Watt
Summary: This study aims to determine if stereotactic body radiation therapy (SBRT) added to systemic therapy can significantly improve outcomes for patients with advanced stage non-small cell lung cancer (NSCLC) without PD-L1 protein expression. The trial will compare SBRT plus systemic therapy with systemic therapy alone and evaluate progression-free and overall survival. This multi-institutional trial will provide further insight into the efficacy of combining SBRT with systemic therapy.
CLINICAL LUNG CANCER
(2022)
Review
Oncology
R. S. Bhangoo, T. W. Cheng, M. M. Petersen, C. S. Thorpe, T. A. DeWees, J. D. Anderson, C. E. Vargas, S. H. Patel, M. Y. Halyard, S. E. Schild, W. W. Wong
Summary: This article characterizes radiation recall dermatitis (RRD), a skin reaction triggered by subsequent systemic therapy, and compares the most common drug classes implicated in this phenomenon.
SEMINARS IN ONCOLOGY
(2022)
Article
Biology
Dirk Rades, Cansu Delikanli, Steven E. Schild, Charlotte Kristiansen, Soren Tvilsted, Stefan Janssen
Summary: Decisions regarding personalized treatment for brain metastases should consider the patient's estimated lifespan, which can be determined using survival scores. In a study of very elderly patients (>= 80 years) with brain metastases who underwent whole-brain radiotherapy, a new survival score showed higher accuracy in predicting death and survival compared to an existing tool. The new score appears to be preferable, but further validation is needed.
Article
Oncology
William W. Wong, Eric M. Anderson, Homan Mohammadi, Thomas B. Daniels, Steve E. Schild, Sameer R. Keole, C. Richard Choo, Katherine S. Tzou, Alan H. Bryce, Thai H. Ho, Fernando J. Quevedo, Sujay A. Vora
CLINICAL GENITOURINARY CANCER
(2017)